Thursday , October 28 2021

Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months

Aurobindo Pharma is expecting to receive an approval for its first biosimilar product in the US in the next 12-18 months, while in Europe, the company hopes a green signal by 2022.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'